HIV-1 DNA burden dynamics in CD4 T cells and monocytes in patients undergoing a transient therapy interruption

Journal of Medical Virology

Volumn 74, Issue 3, 2004, Pages 373-381

  Garbuglia, Anna Rosa ^a   Calcaterra, Silvia ^a   D'Offizi, Gianpiero ^a   Topino, Simone ^a   Narciso, Pasquale ^a   Lillo, Flavia ^b   Girardi, Enrico ^a   Capobianchi, Maria Rosaria ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

ART; HIV 1 DNA burden; HIV 1 reservoir; TTI

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; VIRUS DNA;

ADULT; ARTICLE; CELL DEATH; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; MALE; MONOCYTE; NONHUMAN; SIDE EFFECT; T LYMPHOCYTE; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; BASE SEQUENCE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DNA, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MONOCYTES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 4644310505     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20188     Document Type: Article

References (38)

1. Abbate I, Dianzani F, Turriziani O, Antonelli G, D'Offizi G, Galati V, Pierdominici M, Pandolfi F, Capobianchi MR. 2001. Changes in host cell molecules acquired by circulating HIV-1 in patients treated with HAART. AIDS 15:11-16.
2. Aleman S, Soderbarg K, Visco-Comandini U, Sitbon G, Sonnerborg A. 2002. Drug resistance at low viremia in HIV-1-infected patients with antiretroviral combination therapy. AIDS 16:1039-1044.
3. Calcaterra S, Cappiello G, Di Caro A, Garbuglia AR, Benedetto A. 2001. Comparative analysis of total and integrated HIV-1 DNA in peripheral CD4 lymphocytes and monocytes after long treatment HAART. J Infect 43:239-245.
4. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. 1998. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving protease inhibitors. AIDS 12:F51-F58.
5. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS. 1997. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 94:13193-13197.
6. D'Offizi G, Montesano C, Agrati C, Gioia C, Amicosante M, Topino S, Narciso P, Pucillo LP, Ippolito G, Poccia F. 2002. Expansion of preterminally differentiated CD8 T cells in chronic HIV-positive patients presenting a rapid viral rebound during structured treatment interruption. AIDS 16:2431-2438.
7. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM. 2001. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 344:473-480.
8. Dybul M, Daucher M, Jensen MA, Hallahan CW, Chun TW, Belson M, Hidalgo B, Nickle DC, Yoder C, Metcalf JA, Davey RT, Ehler L, Kress-Rock D, Nies-Kraske E, Liu S, Mullins JI, Fauci AS. 2003. Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active therapy. J Virol 77:3229-3237.
9. Elbeik T, Hoo BS, Campodonico ME, Dileanis J, Fay FF, Bortolozzi RL, Benetti MS, Fay OH, Marlowe N, Petrauskene O, Chernoff D, Smith L, Ng VL. 2001. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/ml that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy. J Hum Virol 4:317-328.
10. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwic KK, Margolick J, Broookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300.
11. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5:512-517.
12. Flynn TE, Bricker LA. 1999. Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann Intern Med 131:548.
13. Frenkel LM, Wang Y, Learn GH, McKernan JL, Ellis GM, Mohan KM, Holte SE, De Vange SM, Pawluk DM, Melvin AJ, Lewis PF, Heath LM, Beck IA, Mahalanabis M, Naugler WE, Tobin NH, Mullins JI. 2003. Multiple viral genetic analyses detect low-level human immunodeficiency virustype 1 replication during effective highly active antiretroviral therapy. J Virol 77:5721-5730.
14. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, Perelson AS, Wolinsky SM. 1999. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. New Engl J Med 340:1614-1622.
15. Heath KV, Hogg RS, Chan KJ, Harris M, Montessori V, O'Shaughnessy MV, Montanera JS. 2001. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 15:231-239.
16. Ho DD, Rota TR, Hirsch MS. 1986. Infection of monocytes/macrophages by human T lymphotropic virus type III. J Clin Invest 77:1712-1715.
17. Kijak GH, Simon V, Balfe P, Vanderhoeven J, Pampuro SE, Zala C, Ochoa C, Cahn P, Markowitz M, Salomon H. 2002. Origin of human immunodeficiency virus typel quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure. J Virol 76:7000-7009.
18. Kulkosky J, Pomerantz RJ. 2002. Approaching eradication of Highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoir with immune activation therapy. Clin Infect Dis 35:1520-1526.
19. Lafeuillade A, Poggi C, Hittinger G, Counillon E, Emilie D. 2003. Predictor of plasma human immunodeficiency virus typel RNA control after discontinuation of active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and Immune-based therapies. J Infect Dis 188:1426-1432.
20. Lambotte O, Taoufik Y, de Goer MG, Wallon C, Goujard C, Delfraissy JF. 2000. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J Acquir Immune Defic Syndr 23:114-119.
21. Miller V. 2001. Structured treatment interruptions in antiretroviral management of HIV-1. Curr Opin Infect Dis 14:29-37.
22. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. 1998. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 351:871-875.
23. Nicholson JK, Cross GD, Callaway CS, McDougal JS. 1986. In vitro infection of human monocytes with T lymphotropic virus type III/ lymphadenopathy-associated virus (HTLV-III/LAV). J Immunol 137:323-329.
24. Ortiz GM, Wellons M, Brancato J, Vo HT, Zinn RL, Clarkson DE, Loon K, Bonhoeffer S, Miralles GD, Bartlett JA, Nixon DF. 2001. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci USA 98:13288-13293.
25. Pellegrin I, Caumont A, Garrigue I, Merel P, Schrive MH, Fleury H, Dupon M, Pellegrin JL, Ragnaud JM. 2003. Predictive value of provirus load and DNA Human Immunodeficiency virus genotype for successful abacavir-based simplified therapy. J Infect Dis 179:361-366.
26. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, Ho DD. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387:188-191.
27. Pierson T, McArthur J, Siliciano RF. 2000. Reservoir for HIV-1: Mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 18:665-708.
28. Ririe KM, Rasmussen RP, Wittwer C. 1997. Product differentiation by analysis of DNA melting curves during the polymerase chain reaction. Anal Biochem 245:154-160.
29. Riva E, Antonelli G, Scagnolari C, Pistello M, Capobianchi MR, Monforte Ad A, Pezzotti P, Dianzani F; I.C.O.N.A. Study Group. 2003. Human Immunodeficiency Virus (HIV) DNA load and level of immunosuppression in treatment-naive HIV-1-infected patients. J Infect Dis 87:1826-1828.
30. Ruiz L, Carcelain G, Martinez-Picado J, Frost S, Marfil S, Paredes Romeu J, Ferrer E, Morales-Lopetegi K, Autran B, Clotet B. 2001. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS 15:F19-F27.
31. Saiki RK, Scharf S, Faloona F, Mullis KB, Horn GT, Erlich HA, Arnheim N. 1985. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230:1350-1354.
32. Schwieghardt B, Ortiz GM, Grant RM, Wellons M, Miralles GD, Kostrikis LG, Bartlett JA, Nixon DF. 2002. Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. AIDS 16:2342-2344.
33. Sharkey ME, Teo I, Greenough T, Sharova N, Luzuriaga K, Sullivan JL, Bucy RP, Kostrikis LG, Haase A, Veryard C, Davaro RE, Cheeseman SH, Daly JS, Bova C, Ellison RT III, Mady B, Lai KK, Moyle G, Nelson M, Gazzard B, Shaunak S, Stevenson M. 2000. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med 6:76-81.
34. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF. 2003. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4(+) T cells. Nat Med 9:727-728.
35. Sonza S, Mutimer HP, Oelrichs R, Jardine D, Harvey K, Dunne A, Purcell DF, Birch C, Crowe SM. 2001. Monocytes harbour replication-competent, non latent HIV-1 in patients on highly active antiretroviral therapy. AIDS 15:17-22.
36. Thiebaut R, Daucourt V, Mercie P, Ekouevi DK, Malvy D, Morlat P, Dupon M, Neau D, Farbos S, Marimoutou C, Dabis F. 2000. Lypodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France,1999. Groupe d'Epidemiologie Clinique du syndrome d'immunodeficience acquise en Aquitaine. Clin Infect Dis 31:1482-1487.
37. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295.
38. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, Talal A, Racz P, Perelson AS, Korber BT, Markowitz M, Ho DD. 1999. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 340:1605-1613.